跳至主要内容
临床试验/NCT05551832
NCT05551832招募中3 期

Prevalence of Marginal Ulcer After PPPD and Preventive Effect of Proton Pump Inhibitor in Korea: A Prospective Multicenter Study

Gangnam Severance Hospital1 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2022年10月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
360
试验地点
1
主要终点
Marginal ulcer incidence

研究概览

简要总结

This research is to determine which medication, Esmesol (PPI) or Placebo works best at reducing the chance that a patient will get an marginal ulcer after pancreaticoduodenectomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is age ≥ 19 years Patient meets the criteria for Open/MIS PPPD Females only: Patient is willing to take a urine pregnancy test

排除标准

  • Subject allergic to ESMESOL Patient receiving antifungal (i.e. ketoconazole or itraconazole) Hepatic insufficiency History of Crohns disease History of Zollinger-Ellison disease Patient received an investigational drug within 30 days of enrollment Previous Gastric Surgery HX

研究组 & 干预措施

Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months

Placebo Comparator

Placebo beginning day of hospital discharge following PPPD for 6 months

干预措施: Arm I (Placebo), (Drug)

Esmesol 40mg after PPPD for 6 months

Experimental

Esmesol 40mg beginning day of hospital discharge following PPPD for 6 months

干预措施: Arm II (ESMESOL) (Drug)

结局指标

主要结局

Marginal ulcer incidence

时间窗: Time Frame: during first 6 months after surgery

Number of Participants occurs Endoscopic visualization of presence or absence of marginal ulcers

次要结局

  • QOL(Time Frame: during first 6 months after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Joon Seong Park

professor

Gangnam Severance Hospital

研究点 (1)

Loading locations...

相似试验